Cargando…
Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
BACKGROUND: Randomised controlled trials have evaluated the recombinant tetravalent dengue vaccine (CYD-TDV). However, individual results may have little power to identify differences among the populations studied. OBJECTIVE: To evaluate efficacy, immunogenicity and safety of CYD-TDV in the preventi...
Autores principales: | Rosa, Bruno Rodrigues, da Cunha, Antonio José Ledo Alves, Medronho, Roberto de Andrade |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429993/ https://www.ncbi.nlm.nih.gov/pubmed/30872537 http://dx.doi.org/10.1136/bmjopen-2017-019368 |
Ejemplares similares
-
Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years: Phase II randomized controlled trial in Singapore
por: Sin Leo, Yee, et al.
Publicado: (2012) -
Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
por: Malisheni, Moffat, et al.
Publicado: (2017) -
Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America
por: Carpp, Lindsay N., et al.
Publicado: (2020) -
Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
por: Tran, Ngoc Huu, et al.
Publicado: (2019) -
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
por: Forrat, Rémi, et al.
Publicado: (2021)